Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469454 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL469451 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL469447 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL307626 | 0.85 | NPC1 (0.65) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2832021 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL27918770 | 0.83 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL11649083 | 0.83 | NPC1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2010247 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL5261314 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL1066371 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | claimed |
| EP-0868535-B2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2006-01-04 | — | — | EP | claimed |
| EP-0990047-B1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | QIAGEN GENOMICS INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030077595-A1 | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays | QIAGEN GENOMICS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020119456-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | AGILENT TECHNOLOGIES, INC. | 2002-08-29 | — | — | US | claimed |
| US-6312893-B1 | GENERATING TAGGED NUCLEIC ACID FRAGMENTS WHICH ARE COMPLEMENTARY TO SELECTED TARGET NUCLEIC ACID MOLECULE; SEPARATION OF TAGGED FRAGMENTS; CLEAVING THE TAGS; DETECTING TAGS BY NON-FLUORESCENT SPECTROMETRY OR POTENTIOMETRY | QIAGEN GENOMICS, INC. | 2001-11-06 | — | — | US | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | SMN1; SMN2 936/4885NPC1 4623/4885RAB9A 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.